메뉴 건너뛰기




Volumn 83, Issue 3, 2007, Pages 181-182

Uncertainties of routine HLA B*5701 testing in black African HIV cohorts in the UK

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; HLA B ANTIGEN;

EID: 34347225618     PISSN: 13684973     EISSN: None     Source Type: Journal    
DOI: 10.1136/sti.2006.022335     Document Type: Note
Times cited : (10)

References (9)
  • 1
    • 12144287198 scopus 로고    scopus 로고
    • Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant
    • Martin A, Nolan D, Gaudieri S, et al. Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant. Proc Natl Acad Sci USA 2004;101:4180-5.
    • (2004) Proc Natl Acad Sci USA , vol.101 , pp. 4180-4185
    • Martin, A.1    Nolan, D.2    Gaudieri, S.3
  • 2
    • 33745295856 scopus 로고    scopus 로고
    • Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study
    • Rauch A, Nolan D, Martin A, et al. Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study. Clin Infect Dis 2006;43:99- 102.
    • (2006) Clin Infect Dis , vol.43 , pp. 99-102
    • Rauch, A.1    Nolan, D.2    Martin, A.3
  • 3
    • 33845565479 scopus 로고    scopus 로고
    • Screening for HLA-B*5701 reduces the frequency of abacavir hypersenitivity reactions
    • 24-26 September, San Francisco, California, USA abstract 14, accessed 16 Dec
    • Reeves I, Churchill D, Fisher M. Screening for HLA-B*5701 reduces the frequency of abacavir hypersenitivity reactions. 8th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, 24-26 September 2006, San Francisco, California, USA (abstract 14). http://www.intmedpress.com/lipodystrophy/webcasts/session4cfm (accessed 16 Dec 2006).
    • (2006) 8th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV
    • Reeves, I.1    Churchill, D.2    Fisher, M.3
  • 4
    • 12144291194 scopus 로고    scopus 로고
    • Differentiation between African populations is evidenced by the diversity of alleles and haplotypes of HLA class I loci
    • Cao K, Moormann AM, Lyke KE, et al. Differentiation between African populations is evidenced by the diversity of alleles and haplotypes of HLA class I loci. Tissue Antigens 2004;63:293-325.
    • (2004) Tissue Antigens , vol.63 , pp. 293-325
    • Cao, K.1    Moormann, A.M.2    Lyke, K.E.3
  • 5
    • 12144291646 scopus 로고    scopus 로고
    • CNA30032 Study Team. Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some but not all populations
    • Hughes AR, Mosteller M, Bansal AT, et al. CNA30032 Study Team. Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some but not all populations. Pharmacogenomics 2004;5:203-11.
    • (2004) Pharmacogenomics , vol.5 , pp. 203-211
    • Hughes, A.R.1    Mosteller, M.2    Bansal, A.T.3
  • 6
    • 20644470742 scopus 로고    scopus 로고
    • Clinical and immunogenetic correlates of abacavir hypersensitivity
    • Phillips EJ, Wong GA, Kaul R, et al. Clinical and immunogenetic correlates of abacavir hypersensitivity. AIDS 2005;19:979-81.
    • (2005) AIDS , vol.19 , pp. 979-981
    • Phillips, E.J.1    Wong, G.A.2    Kaul, R.3
  • 7
    • 20144380564 scopus 로고    scopus 로고
    • HLA-B*5701 typing by sequence-specific amplification: Validation and comparison with sequence-based typing
    • Martin AM, Nolan D, Mallal S. HLA-B*5701 typing by sequence-specific amplification: validation and comparison with sequence-based typing. Tissue Antigens 2005;65:571-4.
    • (2005) Tissue Antigens , vol.65 , pp. 571-574
    • Martin, A.M.1    Nolan, D.2    Mallal, S.3
  • 8
    • 3042634326 scopus 로고    scopus 로고
    • Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity
    • Hughes DA, Vilar FJ, Ward CC, et al. Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity. Pharmacogenetics 2004;14:335-42.
    • (2004) Pharmacogenetics , vol.14 , pp. 335-342
    • Hughes, D.A.1    Vilar, F.J.2    Ward, C.C.3
  • 9
    • 30944449815 scopus 로고    scopus 로고
    • Personalised medicines: Hopes and realities
    • The Royal Society, Report September
    • The Royal Society. Personalised medicines: hopes and realities. Report September 2005.
    • (2005)


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.